Trust Co lifted its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 13.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,634 shares of the pharmaceutical company’s stock after purchasing an additional 3,285 shares during the quarter. Trust Co’s holdings in GlaxoSmithKline were worth $1,163,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Wealthcare Advisory Partners LLC grew its holdings in shares of GlaxoSmithKline by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after purchasing an additional 3,351 shares in the last quarter. FTB Advisors Inc. grew its holdings in shares of GlaxoSmithKline by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after purchasing an additional 539 shares in the last quarter. Advisory Services Network LLC boosted its stake in GlaxoSmithKline by 24.2% in the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after buying an additional 788 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in GlaxoSmithKline by 3.5% in the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after buying an additional 148 shares in the last quarter. Finally, Coastline Trust Co acquired a new stake in GlaxoSmithKline in the 2nd quarter valued at $202,000. 9.82% of the stock is currently owned by institutional investors.

Shares of GlaxoSmithKline plc (NYSE GSK) traded down $0.55 on Thursday, reaching $36.40. The company’s stock had a trading volume of 5,303,100 shares, compared to its average volume of 6,431,743. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline plc has a 52-week low of $34.52 and a 52-week high of $44.53. The company has a market cap of $89,980.00, a P/E ratio of 28.44, a price-to-earnings-growth ratio of 2.15 and a beta of 0.97.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be given a $0.5037 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 annualized dividend and a yield of 5.54%. GlaxoSmithKline’s payout ratio is presently 155.47%.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.00% of the company’s stock.

Several brokerages recently commented on GSK. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Investec lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. Finally, Bank of America lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research note on Thursday, October 26th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have issued a buy rating to the company. GlaxoSmithKline has a consensus rating of “Hold” and a consensus target price of $38.57.

ILLEGAL ACTIVITY WARNING: “Trust Co Purchases 3,285 Shares of GlaxoSmithKline plc (GSK)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2018/01/11/trust-co-purchases-3285-shares-of-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related stocks with our FREE daily email newsletter.